Browsing Tag
David Stamler
2 posts
Alterity Therapeutics (ASX:ATH) has FDA clarity, but Phase 3 funding now tests the rally
Alterity has FDA clarity for ATH434. The bigger question is whether ASX:ATH can fund and execute Phase 3 without losing momentum.
Alterity Therapeutics launches phase 2 trial of MSA candidate ATH434
Alterity Therapeutics said that it has launched a phase 2 clinical trial of its lead candidate ATH434 in…